Back to search

Switzerland· 69230003

Nexpovio 20 mg, Filmtabletten

A selinexor product containing selinexorum, registered in Switzerland by Stemline Therapeutics Switzerland GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01XX66

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedNexpovio 20 mg, FilmtablettenATCL01XX66REGISTER NO.69230003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Selinexor is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XX66 (selinexor), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Selinexor · ATC L01XX66

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selinexor costs, country by country.

Normalised to the WHO defined daily dose (18.6 mg), the median price runs from $0.99 in France to $402.73 in Switzerland — a ×406 gap.

  • Switzerland: $402.73 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Selinexor · price per daily dose (18.6 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$402.73
  • FR France$0.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
selinexorum
Manufacturer
Stemline Therapeutics Switzerland GmbH
Country
Switzerland (CH)
ATC code
L01XX66
ATC class
Selinexor
Defined daily dose
18.6 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680692300034
    Blist 16 Stk
    CHF 5746.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

72 interactions on record for selinexor.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Selinexor · interactions on record

72 records

  • 29 severe
  • 43 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selinexor in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selinexor products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Nexpovio
  • Liechtenstein · Nexpovio
  • Norway · Nexpovio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5484fda7-0ffd-43e6-98b3-625f58fbbb07
GET /v1/drugs/5484fda7-0ffd-43e6-98b3-625f58fbbb07?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "selinexorum 20 mg",
  "valid_from": "2026-02-01",
  "limitations": "[{\"description\":\"Nur nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Eine Kostengutsprache hat den entsprechenden Indikationscode (21811.01) zu enthalten.<br>\\nNEXPOVIO wird in Kombination mit Dexamethason für die Behandlung des Multiplen Myeloms bei erwachsenen Patienten, die zuvor mindestens vier Therapielinien erhalten haben und deren Erkrankung gegenüber mindestens zwei Proteasom-Inhibitoren, zwei immunmodulatorischen Arzneimitteln und einem monoklonalen Anti-CD38-Antikörper refraktär ist und bei denen unter der letzten Therapie eine Progression der Erkrankung aufgetreten ist, vergütet.<br>Nur bis zur Progression der Krankheit.<br>\\nZudem gelten folgende Vergütungskriterien:<br>\\n- Mindestens eine messbare Erkrankung gemäss den Kriterien der IMWG<br>\\n- ECOG Performance-Status von ≤ 2<br>\\n- ausreichende hepatische, renale und hämatopoetische Funktion<br>\\n<br>\\nDie Zulassungsinhaberin Stemline Therapeutics Switzerland GmbH erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung NEXPOVIO einen Betrag von Fr. 934.92 zurück. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21811.01<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21811.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-02-01\",\"validTo\":\"2028-01-31\"}]",
  "galenic_form": "Filmtabl 20 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2026-02-01",
  "self_retention_pct": 10
}

See everything about selinexor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.